The Changing Paradigm in Preclinical Toxicology: in vitro and in silico Methods in Liver Toxicity Evaluations

Fozia Noor

Université du Luxembourg

Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/appamet

Part of the Bioethics and Medical Ethics Commons, Design of Experiments and Sample Surveys Commons, and the Laboratory and Basic Science Research Commons

Recommended Citation


This material is brought to you for free and open access by WellBeing International. It has been accepted for inclusion by an authorized administrator of the WBI Studies Repository. For more information, please contact wbisr-info@wellbeingintl.org.
CHAPTER 25

The Changing Paradigm in Preclinical Toxicology: *in vitro* and *in silico* Methods in Liver Toxicity Evaluations

*Fozia Noor*
Luxembourg Centre for Systems Biomedicine (1-CSB), Université du Luxembourg, Esch-sur-Alzette, Luxembourg
Fozia.noor@uni.lu

1 Toxicology in the 21st Century

Toxicology is one of the sciences that have slowly but surely embraced technology and new methods, focusing on high throughput and high content screenings, *omics* technologies, and mathematical modeling. Thus, a transition in toxicology—from a traditional reductionist paradigm towards 21st century methods based on human biology and holistic multi-*omics* studies—is now becoming a reality. With the recent advances in human-cell cultivation techniques, allowing *in vivo*-like *in vitro* long-term functionality, there is a shift in focus towards the mechanistic details of the adverse effects “over time” aimed at a better understanding of the dynamics of biological processes.

*In vitro* methods, based on human primary cells, cell lines, and genetically modified reporter cell lines, have greatly expanded the scope of *in vitro* toxicology. Other significant progress in the area of human-induced pluripotent stem cells (hiPSCs) (Asgari et al., 2010; Schwartz et al., 2014; Shinde et al., 2016; Shtrichman, Germanguz and Itskovitz-Eldor, 2013) is allowing the application of patient and disease-specific hiPSCs (Ghodsizadeh et al., 2010; McCracken et al., 2014; Siller et al., 2013). Moreover, the tools of precise genome editing with engineered nucleases, such as the zinc finger nucleases (ZFNs), the transcription activator-like effector nucleases (TALENs) and, more recently, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated Cas9 technology (Gaj, Gersbach and Barbas, 2013; Kim, 2016; Komor, Badran and Liu, 2017) have opened up tremendous opportunities for the development of cell lines, especially those of human origin (Tobita, Guzman-Lepe and de L’Hortet, 2015). CRISPR/Cas9 technology was reported for genome editing in hiPSCs (Flaherty and Brennand, 2015; Li et al., 2014; Seah et al., 2015; Suzuki et al., 2014). Another study reported on the simultaneous reprogramming and...
gene correction of patient fibroblasts (Howden et al., 2015). Since 2015, more than 3,000 articles were published on studies using CRISPR/Cas9 genome editing, including more than 900 articles using the technology in mammalian cells (PubMed, accessed June 11, 2017). With further technological developments, these human in vitro cellular models shall be highly useful in the screening of compounds for personalized medicine, allowing optimum therapy with minimum or no adverse effects, and in the study of adverse outcomes in different strata of population. In addition to high-content screening, where several parameters are measured as simultaneous readouts in single cells (Gasparri, 2009), high-content imaging will play an important complimentary role in systems biology approaches (van Vliet et al., 2014). High-content platforms have been already used for the screening of compounds (Bale et al., 2014; Sirenko et al., 2014; Tolosa et al., 2014).

Modern technologies of omics and high-content imaging are resulting in immense data sets which require large-scale data-processing tools. Powerful bioinformatics’ tools are also required for data integration and the overarching interpretation of biological data from disparate sources. The inherent complexity of biological systems is a challenge that is expected to be overcome by computational modeling of biological systems. Toxicology is, therefore, aiming at the integration of a tremendous amount of diverse information—at various levels of biological hierarchy (genome, transcriptome, proteome, and metabolome) and biological structure (organelles, cells, tissues, organs, and organism)—with computational tools for understanding and predicting biological behavior (e.g., adverse effect) under given conditions (e.g., perturbation due to a toxin). This rejuvenated toxicology in modern terms is referred to as systems toxicology (see Figure 25.1).

1.1 Systems Toxicology

The term systems toxicology is derived from systems biology and could be defined as the study of biological systems, using omics technologies, with a focus on the mechanisms underlying complex biological processes, their interactions and perturbations in response to a toxin combined with mathematical data integration and modeling. Systems toxicology, therefore, aims at understanding and exploring the way that different biological components are orchestrated as an ensemble in cells, tissues, and organisms.

A biological system usually consists of a large number of functionally diverse and/or multitasking components interacting together in a nonlinear fashion in, so-called, biological networks spread over several levels of biological organization (Kitano, 2002). Systems biology aims at understanding the structural and functional connectivity in biological networks or simply the biological
homeostasis. Almost 150 years ago, the French physiologist, Claude Bernard, put forward the idea that free life is based on the constancy of the internal environment. Later, in 1922, the American physiologist, Walter Canon, described homeostasis as the key principle of life. According to Hans Seyle (1956), since systems are robust, a system under stress will try to achieve a new homeostasis to maintain its functions, until the stress crosses a certain threshold, and the system collapses. Similarly, biological systems exposed to a stressor/toxin will try to adapt and survive. Acute exposure for a short period may constitute a temporary stress that may, or may not, manifest as a toxic effect(s), while the biological system tries to adapt or compensate. However, acute exposure at a very high dose may lead to acute exhaustion of the system's resources to cope and may lead to rapid system breakdown. On the other hand, upon repeated or chronic exposure to low levels of stress, the system inevitably acquires a new homeostasis. This new homeostasis may be accompanied by adverse effects.
or disease development (e.g., depression, cancer) over the period of exposure. Upon accumulation of long-term stress, when the system’s capacity to maintain altered homeostasis is exhausted, the system will break down, ultimately leading to the extinction of the system.

Understanding biological processes means a step towards understanding the mechanisms of adverse effects, which in turn means understanding the molecular and functional changes in a system upon perturbation of the system’s homeostasis. A mechanistic understanding requires system-wide quantitative measurements of these molecular and functional changes. Recent progress in omics technologies is playing a decisive role in linking system-level understanding to quantitative molecular knowledge (Ideker, Galitski and Hood, 2001). An essential part of systems toxicology is the mathematical modeling of biological responses based on mechanisms and the use of such computational models for predicting responses by changing the parameters of perturbation. Systems toxicology is, therefore, the integration of traditional toxicology with modern techniques of integrated testing strategies, high-throughput screenings, pharmacokinetics/pharmacodynamics knowledge, high-content screenings, omics technologies, in silico tools and modeling. Recent advances in cell-culture techniques, mimicking in vivo organs, are allowing for the acquisition of physiologically relevant information that will enhance pathways-based understandings for the discovery of novel targets and prediction of risks of adverse outcomes.

1.2 Pathways of Toxicity
The concept of pathways of toxicity (PoTs) evolved after the famous report from the United States National Research Council in 2007, titled Toxicology in the 21st Century, which recommended a shift in testing from animals to human-cell systems for the assessment of toxicity pathways (Krewski et al., 2010). Other terms, such as the mode of action (MOA) and the adverse outcome pathways (AOP) are currently used to structure and describe biological processes over biochemical pathways leading to adverse effects. This information can be mapped on various levels of biological organization (e.g., from cells to populations and even ecologies) (see Figure 25.2).

A PoT is a cellular response pathway, which upon sufficient perturbation will lead to an adverse health effect. A PoT should describe the molecular basis of the adverse response. It is assumed that a limited number of PoTs are conserved over cell types, organs, and even species, and should mediate the same adverse outcome (Bouhifd et al., 2015). PoTs aim at molecular annotations of network perturbations and their causes from high-content phenotyping (Hartung and McBride, 2011). It should be possible to derive PoTs from simple in vitro tests, as in the ToxCast program in the US, which evaluated 2,000 compounds.
in more than 700 assays and around 300 signaling pathways (Attene-Ramos et al., 2013; Hsieh et al., 2017).

The molecular mechanisms over a series of causal events can be described as the MOA. It is important to distinguish a mechanism of action from the mode of action. A mechanism of action describes the primary chemico-biological interaction between a compound and a structural moiety in a biological system (Blaauboer and Andersen, 2007). This is more or less equivalent to the molecular initiating event in an AOP. The MOA describes functional and structural changes that follow the primary interaction of a compound with its biological target and result in quantifiable changes at the organism level (Blaauboer and Andersen, 2007). The MOA-based paradigm is based on the concept of toxicity pathways. A PoT represents a set of molecular events that ultimately lead to a measurable adverse outcome associated with the stressor/toxin. As such, MOA and AOP are sometimes used in similar contexts.

1.3 Adverse Outcome Pathways

The concept of AOP was developed in the field of ecotoxicology. Ankley et al. (2010, p. 730) defined AOP as “a conceptual construct that portrays existing knowledge concerning the linkage between a direct molecular initiating event and an adverse outcome at a biological level of organization relevant to risk assessment”. The term AOP is a misnomer, since pathways are not intrinsically adverse or non-adverse but they may lead to adverse effects or disease after perturbation. The AOP framework allows the organization and structuring of information for improved decision making in risk assessment (Edwards et al., 2016).

The concept of AOP is now embraced by scientists all over the world, with international efforts for harmonization and guidance on AOP construction and development, such as the Organisation for Economic Co-operation and Development (OECD) guideline (2013) and recently published AOP development strategies, principles, and best practices (Villeneuve et al., 2014a,b). AOPS have
been described for skin sensitization, liver cholestasis, liver steatosis, and fibrosis (OECD, 2012; Vinken et al., 2013; Willett et al., 2014). More recently, there are suggestions that the AOP framework can also be used for organizing, structuring, and describing the pathways involved in diseases (Langley et al., 2017; Noor, 2015).

An AOP will begin upon exposure to a compound. The interaction of that compound with the biological target will depend on its physico-chemical properties and could be analyzed using methods of quantitative structure-activity relationships (QSARs). The interaction of the compound with its biological target is the molecular initiating event. This will in turn lead to causal chain of events at different levels of biological organization, with effects at the organelle, cellular, and tissue levels. Depending on the intensity and duration of the exposure, these effects will affect the function(s) of the organ, which will initially try to adapt to the perturbation to achieve a new homeostasis. However, persistent stress will ultimately lead to adverse effect(s) at the organ level (see Figure 25.3). With time, organ level effects can spread to the whole organism. In epidemiology, many affected organisms will lead to population and ecology effects.

Initially, AOPs were thought to be linear constructs with key events causally linked with each other and occurring at different levels of biological organization (Landesmann et al., 2013). However, biological systems are highly complex and interconnected, in addition to being very robust, and show adaptive responses to stress stimuli. Biological processes are nonlinear and highly wired together with feedback loops and cross regulation. Modern AOPs are chemically independent, modular, and connected over networks (Villeneuve et al., 2014a). The concept of key event relationships has been used to explain quantitative connections between several AOPs and more than one adverse

---

**FIGURE 25.3** An AOP framework to explain multilevel effects beginning with an initial triggering event (molecular initiating event), followed by a series of intermediary events (key events) that lead to an adverse outcome.

ADAPTED FROM LANDESANN ET AL. (2013)
outcome (Figure 25.4). These connections help to identify gaps and uncertainties in an AOP. An adverse outcome may also lead to another adverse outcome. For prediction, quantitative response relationships among key events within an AOP are required and make use of weighting and probabilistic and mechanistic approaches (Becker et al., 2015; Perkins et al., 2015). It is expected that quantitative AOP and quantitative AOP networks will have quantitative key event relationships and this may help define an AOP score for the prediction.

Although an AOP is a pragmatic way of organizing information of biological relevance and facilitates causal links with multilevel information, there are many challenges to their wide application. An AOP should not only give information about the structure of the system but also provide important clues

FIGURE 25.4  Adverse outcome pathways. (A) a linear AOP showing molecular initiating event (MIE) as the interaction between chemical and its biological target leading to a chain of causal key events (KE) resulting in an adverse outcome (AO). (B) an AOP network with multiple pathways and key events (KE) leading to one or more adverse outcomes. The quantitative correlation between two key events (KER) would determine the intensity of the involvement of that pathway.

ADAPTED FROM GARCIA-REYERO 2015
on the dynamics of the system. It is highly recommended for an AOP to have direct human relevancy, and an AOP based only on animal data is insufficient. The relationships between molecular initiating events, key events, and adverse outcomes should be predictable. The successful application and adaption of AOPs in toxicology (especially regulatory toxicology) will depend on the effectiveness of an AOP to predict adverse outcomes. Since AOPs are considered living documents that will change with the progressive availability of knowledge, the development of AOPs will proceed in parallel with their use; which will inevitably, in some cases, pose uncertainties. The more nonlinear linkages there are over multiple pathways, the more challenging the task of deriving correlations for prediction. As with other sciences, there is an urgent need for standardization, harmonization, and development of common language(s) to connect and understand different application domains.

2 Preclinical Drug Development

From the discovery of new therapeutic entities to the marketing of the final product, the drug development process mainly deals with preclinical development and clinical trials of, so-called, investigational new drugs. Preclinical drug development focuses on the proof of efficacy and safety of new drugs. The immense technological advancements of recent years have rendered the drug discovery and development process more expensive than ever. At the same time, the success rates have fallen, the regulatory requirements are becoming stricter, and the competition has become fierce. According to the Tufts Center for the Study of Drug Development, in 2014, the cost of drug development was around US$2.6 billion, with preclinical development costs surpassing US$1 billion (Mullin, 2014). Only one in ten drugs entering the clinical phase is approved by the US Food and Drug Administration (FDA), according to a recent report (Hay et al., 2014). The failure of an investigational new drug in the clinical trials may cost billions of dollars (Horton 2004; Lang 2005). Most investigational new drug failures are due to lack of efficacy and/or clinical toxicity. Human safety issues result in about 20% of failed drugs (Kola and Landis, 2004). In 2010, a 10-year survey showed that safety issues remained one of the major bottlenecks in drug development (Waring et al., 2015). The woes of the pharmaceutical industry can continue even after the approval and marketing of a drug, as there is around 5% risk of post-marketing withdrawal due to adverse effects (Smith and Schmid, 2006).

Liver and cardiac toxicity are the major issues in drug development. Liver toxicity alone (until 2014) has resulted in most drug withdrawals. The
regulatory agencies require the testing of acute and repeated-dose toxicity in animals. Although, the pharmaceutical industry is, at present, using a range of high-throughput in vitro assays (some accepted by regulatory bodies) in the initial screening of compounds, there are no accepted in vitro models for repeated-dose, long-term toxicity. The next part of the chapter focuses on the limitations of animal models and emerging new models and technology in the assessment of liver toxicity, followed by in silico computational methods in drug development.

3 Limitations of Animal Models in Liver Toxicity Evaluations

Although in vivo animal testing gives direct evidence of toxicity in a living “intact” organism and allows experiments not possible in humans, it is limited by several serious drawbacks of scientific, economical, and ethical nature. A major limitation is the poor predictive power of animal studies. This poor translation of animal results to humans is mainly due to species-specific differences (Martignoni, Groothuis and de Kante, 2006). Animals predict only 40% of human liver toxicities (Ewart et al., 2014; Olson et al., 2000). Even among different animal species, the correlation is about 60% (Hartung and Daston, 2009), showing differences among test species and the limitation of prediction. The intrinsic differences in animals within the same species provide inconsistent results, especially in the case of oral-dose chronic toxicity. Testing in animals is usually carried out in the highest tolerable doses, which do not reflect human exposure. Equally important, even after standard animal testing, 19% of compounds presumably safe in animals, show toxic effects in human clinical trials and are not pursued further (Sacks et al., 2014). In addition, many drugs proved safe in animal tests and clinical trials, are withdrawn from the market or labeled with black box warnings due to serious side effects. In the past 60 years, there have been more than 450 post-marketing withdrawals of drugs due to hepatotoxicity (Onakpoya, Heneghan and Aronson, 2016).

Species-specific differences are mainly due to differences in the pharmacokinetic parameters, namely absorption, distribution, metabolism, and elimination. Screening in animals is carried out with the assumption that similar reactions of biotransformation and clearance will occur in animals as in humans. However, animals differ from humans in the biotransformation of xenobiotics from Phase 0 (uptake of compounds mainly via transporters), to Phase I (CYP450 metabolism), Phase II (conjugation reactions), and Phase III (excretion/eliminations of the parent compound or metabolites or their conjugates mainly via the transporters). It is now well known that not only are there
differences in the metabolism of substances between animals and humans, but also many molecular mechanisms of human cellular injury are different (Woolbright et al., 2015).

In addition, due to the characteristics inherent to *in vivo* testing, such testing is excessively precautionary; and, therefore, many *potential* therapeutic compounds are screened out. One such example is aspirin, which is considered safe for human beings; it would not have been possible to market aspirin with current methods and criteria for safety (Hartung, 2009). This means that the current methods of screening may also possibly screen out compounds that could otherwise be useful in the therapy of human ailments. Other technical limitations include, low throughput of animal studies, in addition to prolonged study periods in some cases (e.g., carcinogenicity study) (Bucher, 2002).

Although animal testing has provided significant insights into biological processes and has contributed to human safety, the scientific goal of the 21st century should be a move towards human-based *in vitro* methods, with modern tools of systems biology, to bypass the species barrier and to allow better translation.

### 4 *In vitro* Models of Liver Toxicity in Preclinical Drug Development

Traditionally, *in vitro* models refer to cell-cultivation methods of primary cells and cell lines, commonly involving plastic or glass cultivation vessels with a cell-culture medium suitable for a given cell type. Wilhelm Roux, a German zoologist, established the basic principles of tissue culture in 1885, by maintaining tissues in a warm saline solution for several days. Julius Richard Petri, a German microbiologist, owns the credit of inventing the Petri dish in the early 1900s. Modern two-dimensional (2D) cell culture is usually carried out in polymer culture flasks and dishes of multitude formats. Ross Granville Harrison, an American embryologist, is considered the pioneer of 3D cell culture using the hanging drop method (Nicholas, 1961).

Today, 2D cultivation techniques are well established and cells (mostly cell lines) of almost all tissues of human or animal origin are available. There are many advantages to the 2D cultivation of cells, such as simplicity; expertise required; low costs; high number of replicates; and, most importantly, application in high-throughput screening in multi-well plates, with the possibility of miniaturization and robotic automation, minimizing human bias and error as well as ensuring high precision. In addition, less material (cells and culture media as well as test substance) is required with fewer ethical concerns. A battery
of simple and complex 2D in vitro assays can predict up to 80% of human hepatotoxicity (Noor et al., 2009; Vernetti et al., 2017).

Nevertheless, 2D cultivation of cells involves maintaining the cells in an unnatural and artificial environment, whereby they lose their organ- and tissue-specific architecture and organization. Other factors, such as medium change, cell density to surface ratios, lack of flow and sheer tension, and unphysiological oxygen supply are other major limitations. Another commonly encountered problem is the rapid de-differentiation of primary cells, such as the hepatic cells, in 2D cultures, resulting in the loss of functions.

In vivo, cell-to-cell contacts and communication across the extracellular matrix are ensured within a three-dimensional (3D) arrangement. The extracellular matrix regulates cell morphology and gene expression in vivo (Bissell, 2007; Bissell, Hall and Parry, 1982; Le Beyec et al., 2007). A 3D environment influences the epigenetic plasticity of the cells (Spencer, Xu and Bissell, 2007; Xu, Spencer and Bissell, 2007). Conventional 2D hepatic cultures rapidly lose liver-like functionality (Godoy et al., 2013; Paine and Andreakos, 2004), leading to poor concordance between experimental in vitro data and in vivo data, especially with respect to xenobiotic metabolism and transporter activities. Optimization of the culture medium may help in the maintenance of functions for some time (Klein et al., 2014; Mueller et al., 2012). However, modern in vitro methods are more and more focused on the 3D cultivation of cells as organoids or micro tissues that ensure cell-to-cell contacts, cells to be surrounded completely by extracellular matrix, facilitating cell-to-cell communication and signaling (Alepée et al., 2014; Mueller, Heinzle and Noor, 2013).

3D cultures of primary human hepatocytes and human-cell lines, such as HepRG and HepG2, retain long-term viability and maintain liver-specific functions in vitro (Mueller, Koetemann and Noor, 2011a; Mueller et al., 2011b; Gunness et al., 2013; Mueller et al., 2014; van Grunsven, 2017). 3D cultures (also called 3D micro tissues, organoids, and organotypic cultures) in microfluidic devices, are termed biochips (Baudoin et al., 2007), organs on a chip (Bhatia and Ingber, 2014) or body on a chip, where several tissues or organ systems are represented (Marx et al., 2012; Materne et al., 2015a; Materne et al., 2015b; Sung et al., 2014). These emerging technologies allow the study of human physiology and adverse effects in vitro, as they enable analysis of the biochemical and metabolic activities of living cells in functional tissue and organ contexts, while allowing high-resolution, real-time imaging (Bhatia and Ingber, 2014). Although, such advanced 3D culture techniques demand expertise, and usually special equipment/setups, in addition to comparatively higher costs and lower throughputs, they seem to be indispensable for meaningful human-biology based science in future.
Much development effort is underway for a high-throughput generation of the 3D cultures as aggregates (Gevaert et al., 2014), micro-patterned co-cultures (Khetani and Bhatia, 2008) and 3D printing (Billiet et al., 2014). High-content platforms are already used in drug development for the screening of compounds (Bale et al., 2014; Tolosa et al., 2014). At the same time, highly-advanced imaging and other techniques (including automated methods for assessing multiple readouts, such as cell viability, shape of the nuclei, cell area, mitochondrial membrane potential, phospholipids accumulation, cytoskeleton integrity, and apoptosis) are playing an important role in the study of biological pathways (Ramaiahgari et al., 2014; Sirenko et al., 2014). Such high-content and high-throughput platforms are changing the toxicity screening paradigm (Patlewicz et al., 2013), paving the way towards pathway-based, in vitro only, safety assessment (Adeleye et al., 2014; Kleensang et al., 2014).

5 Computational in silico Tools

In silico methods such as quantitative structure activity relationships (QSARs) in predictive toxicology are not new. More than 150 years ago, Cros (1863) linked the toxicity of primary alcohols to their water solubility. Crum-Brown and Fraser (1869) advanced the idea that the biological activity of a compound was linked to its chemical structure. In the 1980s, when pharmaceutical companies were creating libraries of thousands of compounds, methods of QSARs were refined, automatized, and extensively applied. The idea was that the toxicity of a chemical is dependent on specific features of the structure of that chemical. Therefore, similar chemical features are expected to share similar mechanisms of action and could be used for the prediction of activity. Basically, a set of compounds of known activities are used to train computer algorithms to differentiate between active and inactive compounds (Johnson and Maggiora, 1990). QSARs provide a mathematical relationship between a biological activity and one or more molecular descriptors able to predict the activity. These molecular descriptors are quantifiable and, therefore, give a quantitative relation to the toxicity. Modern QSARs are multidimensional (mQSAR) and include multiple representations of the ligand or protein (Tseng et al., 2012; Vedani, Dobler and Lill, 2006).

QSARs are often used in combination with other methods, such as read-across and weight-of-evidence assessments. Read-across is defined by the European Chemicals Agency (2017, p. 6) as “a technique for predicting endpoint information for one substance (target substance), by using data from the same endpoint from (an)other substance(s), (source substance(s))”. A range of in silico
tools are available for grouping the chemicals and read-across (Enoch, Cronin and Ellison, 2011). Publicly available software include, toxicity estimation software tool (TEST), the OECD QSAR toolbox, high-throughput virtual molecule docking (HTVMD), MetaCore, and the TOPKAT model. QSAR methods are increasingly predictive in hazard identification for acute toxicity, genotoxicity, mutagenicity, and bioaccumulation. Nevertheless, QSARS and read-across are limited in the prediction of the pharmacokinetic properties of compounds.

Other in silico methods include computational methods for modeling the pharmacokinetics of compounds and linking this to the biological response. Pharmacokinetics deals with the quantification of drug absorption, distribution, and elimination for the investigation and prediction of blood concentration-time profiles. Pharmacokinetic models can be simple to complex, depending on the level and the quality of information available. Simple models are empirical and can be used for the estimation of clearance and half-life, allowing dosage-regimen calculations (Jones, Mayawala and Poulin, 2013; Klein et al., 2015; Wetmore et al., 2012). Models that are more complex are Physiologically Based Pharmacokinetic (PBPK) models, which are compartment models. These compartments represent tissues and organ spaces and their volumes. As early as 1937, Toerell, one of the pioneers of pharmacokinetics, described the basic principles of a PBPK approach (Teorell, 1937). However, its mathematical complexity and the lack of physiological data needed for the model were significant challenges to its widespread application for many years.

At present, PBPK models are mechanism based and allow extrapolation from high doses to lower doses, from one species to another, and between dose routes. Traditionally, data is generated from in vivo animal and in vitro animal and human studies (see Figure 25.5), in an approach originally described by Sobels for anticancer drugs (Sobels, 1977).

Since PBPK models are based on physiological parameters, it is possible to use them to predict in vivo absorption, distribution, metabolism, and excretion. PBPK modeling is still heavily dependent on animal studies, and very few clinical applications of PBPK models have appeared. The major reason is the lack of human data for validation. However, in vitro systems can be used, to some extent, for the prediction of distribution, metabolism, and elimination (Poulin, 2013; Poulin et al., 2013a, b; Poulin and Haddad, 2013). Using a PBPK model, in vitro tests can also provide parameters that allow the prediction of dose-response in vivo. PBPK modeling not only allows simulation of human pharmacokinetics, it also enables in vitro to in vivo extrapolation. For this purpose, quantitative in vitro data, such as data on tissue distribution, rates of metabolism, rates of interactions with biological macromolecules such
as receptors, changes in cell function and viability, is needed. PBPK modeling combined with other in silico (chemical-related) and in vitro (biology-related) parameter estimations allows for prediction of in vivo exposure equivalent to the in vitro assay concentrations producing an adverse effect. For reliable predictions using such methods, a thorough experimental design with the characterization of the biological system, including the cell model and its characteristics, is essential. Recently, simple PBPK models were combined with acute and long-term dose-response data to calculate oral equivalent doses (Chang et al., 2015; Hamon et al., 2015; Klein et al., 2015; Rotroff et al., 2010; Wetmore et al., 2012; Yoon et al., 2014).

Models based on a systems biology approach are also being developed (Ideker et al., 2001) to allow firm anchorage of PBPK/pharmacodynamic models on a mechanistic basis. This new developing area, currently also referred to as quantitative systems pharmacology, focuses on the drugability of targets in biological systems. Quantitative systems pharmacology, in fact, follows a systems biology approach to drug discovery, aimed at the underlying mechanisms of drug actions on multiscale systems, using iterative computational modeling (Knight-Schrijver et al., 2016; Vernetti et al., 2017).

In general, the advantages of in silico methods are low costs, standardization, equipment needs, throughput, and the tremendous possibility of virtual expansion in terms of chemical space, numbers, and biological response scenarios. However, these methods have their own limitations, such as reliability.
and robustness. These limitations are mainly based on data quality (and in some cases quantity) and the complexity of biological systems. Gene expression and metabolic network models, along with integrated, large multiscale models, are computationally demanding, data intensive, and time consuming.

6 Toxicology in the Coming Years: Challenges and Perspectives

Systems biology—with next generation technologies, such as integrated omics techniques, advanced cell-culture methods, and assays, along with better and faster computational in silico methods—is playing a key role in changing the global mindset towards toxicology. This shift in paradigm will allow for the integration of a human knowledgebase, including network information and in vitro assays providing critical key event parameter values, with less emphasis on in vivo animal data (Edwards and Preston, 2008). For optimal application of systems biology tools, the fundamental construct is to develop adequate and fit-for-purpose in vitro assays to characterize pathway perturbations and predict adverse outcomes due to these perturbations. Future in vitro assays will be based on human cells derived from pluripotent stem cells and human reporter cell lines.

The two most important corner stones of risk assessment are exposure and concentration response. Systems biology provides the framework for bridging exposure to a compound and its causal adverse outcome (Sheldon and Cohen Hubal, 2009). It is essential that in vitro data provide relevant information on the concentration response over time. The perturbations and the concentration in which they occur should reflect human in vivo exposure and effects. However, extrapolation of in vitro results to humans in vivo is sometimes limited due to the fact that nominal concentrations in the in vitro assays are used without consideration of the exposure magnitude, timing, and duration (Coecke et al., 2013). Other factors such as in vivo bioavailability and metabolic clearance are not taken into account, in addition to other in vitro specific parameters, such as plastic binding, cell-surface binding, compound degradation and evaporation (Groothuis et al., 2015).

Furthermore, better tools for the characterization of the biological perturbations leading to adverse effects are needed for a mechanistic understanding of the perturbed pathways. This will require a recapitulation of the toxicity pathway(s) by in vitro assays. In this context, the systems biology approach provides molecular information and key event networks for the comparison of MOA-based pathways. Systems biology measurements will also provide information on overlapping events across multiple pathways. Given that there is often a temporal shift in various omics readouts, it is imperative to conduct
kinetic studies, so that time resolved data could be obtained. Careful design and control of the system is necessary to obtain high-quality data and to reduce uncertainties inherent to *in vitro* systems. A fully integrated systems approach would reduce many uncertainties associated with current risk assessment approaches. The aim is to obtain human-specific, high-quality data at different molecular levels and integrate these with *in silico* tools for the extrapolation and prediction of human adverse effects (see Figure 25.6).

Thus, a systems biology approach could help define MOA, species extrapolation, *in vitro* to *in vivo* extrapolation and provide a mechanistic basis for describing the susceptibility of certain subpopulations. An integrated approach of human *in vitro* and *in silico* methods for *in vivo* exposure is expected to provide a reliable prediction of toxicity. An *in vitro system* that is designed and characterized to provide human *in vivo* relevant information will be the key to successful prediction. Combined with qualitative and quantitative knowledge on perturbations in biological pathways over time, this integrated approach could be a powerful tool for *in vivo* relevant toxicity assessment. Finally, the concept of AOP remains to be developed beyond its limitations and deficiencies to be successful and to gain acceptance by the regulatory agencies in human-risk assessment.

Microfluidic systems, using 3D organotypic cultures for compound screening, is another area with great promise. In the case of liver, it will additionally allow measurements of pharmacokinetic and pharmacodynamic parameters *in vitro*. A challenge will be to include more than one organ on such a platform. Although some systems (see Figure 25.7) are already reported, they are still limited in their wide application. A pragmatic solution will be to combine organ-type cells, according to the scientific need and the data needed.

The establishment of complex cellular models based on co-cultures is another active research area with promise in the quantitative understanding of mechanisms in human health and disease. Organs are complex structures and
their response (manifested as adverse effects or disease) is a joint response of many cell types in communication. Combining different cell types is no trivial task, due to the complex environmental needs of each cell type. The *in vivo* relevance of these systems will have to be validated. Advanced microfluidic systems, in future, will include liver zonation (Vernetti et al., 2017).

The application of hiPSC-derived models in human disease research, in future, will move *in vitro* systems from mostly proliferating cell lines towards patient-specific cells and will, thus, facilitate personalized systems medicine. Human-induced pluripotent stem cells have great potential in toxicological screening, since they provide patient-specific pharmacological responses. Hepatocyte-like cells, derived from hiPSCs cultured on a micropatterned coculture system are reported to predict the hepatotoxicity of test compounds with 65% sensitivity and 100% specificity (Ware et al., 2015). In addition, CRISPER/Cas9 technology provides a range of modified induced pluripotent stem cells (iPSCs), which will allow discovery of novel targets and biomarkers. A whole range of modified iPSCs, after differentiation, could serve not only in regenerative therapy but could be applied in mechanistic research and in the screening of therapeutics (see Figure 25.8).

It is hoped that this shift in paradigm will progress towards evidence-based science and personalized medicine, where clinical observations will be used to design advanced *in vitro* methods based on 3D models, with patient-specific primary or iPSC-derived cellular models (see Figure 25.9). The *omics* data from these models is expected to allow biological target identification and validation. This information will facilitate personalized therapy for a specific patient depending on the patient's genetic background.
**Figure 25.8** Modern cell reprogramming and gene editing tools, allowing modifications of patient-specific iPSCs for use in disease research, toxicology, and screening, in addition to the possibility of cell therapy.

*Image taken from Seah et al. (2015)*

**Figure 25.9** The paradigm shift towards clinical, observations-based, mechanistic investigations *in vitro*, using advanced tools of cell culture and *omics*. These should provide potential biomarkers and targets for exploitation in evidence-based personalized therapy and follow-up.
Clinical observations combined with the omics information, mechanisms, and biomarkers will iterate the whole process in modern systems toxicology. The impact of this approach is, no doubt, beyond toxicology in other fields of health, medicine, drug development, and basic sciences.

References


